Literature DB >> 27995372

Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis.

Honglei Jia1, Qingyu Zhang2, Fanxiao Liu1, Dongsheng Zhou3.   

Abstract

BACKGROUND: The reported roles of matrix metalloproteinase 2 (MMP-2) on the prognosis of patients with epithelial ovarian cancers (EOCs) are inconsistent.
OBJECTIVE: This meta-analysis was performed to evaluate the prognostic significance of MMP-2 for patients with EOCs by analyzing 11 studies.
METHODS: We systematically searched articles in the Cochrane Library, Pubmed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Biological Medical (CBM) Database, updated to February 1st 2015, with the following search terms: ovarian neoplasm OR ovarian tumor OR ovarian carcinoma OR ovarian malignance OR ovarian cancer AND matrix metalloproteinase-2 OR MMP-2.
RESULTS: A total of 11 studies involving 1058 patients with EOCs were in accordance with the inclusion criteria. The pooled HR was 1.09 (95% CI 0.32-1.86, p = 0.006) in patients with overexpression of stromal MMP-2 with significant heterogeneity (I 2 = 53.1%, p = 0.074) between studies. For patients with MMP-2 overexpression in tumor cells, the pooled HR was 1.42 (95% CI 1.14-1.70, p = 0.000) with no significant heterogeneity (I 2 = 43.4%, p = 0.078) between studies. Sensitivity analyses were stable.
CONCLUSIONS: MMP-2 overexpression in tumor cells rather than stroma was significantly associated with poor prognosis in patient with endothelial ovarian cancer; however, the result remains to be confirmed with additional high-quality studies.

Entities:  

Keywords:  MMP-2; Meta-analysis; Ovarian epithelial carcinoma; Prognostic value

Mesh:

Substances:

Year:  2016        PMID: 27995372     DOI: 10.1007/s00404-016-4257-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  10 in total

1.  Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis.

Authors:  Xingchen Liao; Wei Wang; Baoping Yu; Shiyun Tan
Journal:  Cancer Cell Int       Date:  2022-06-14       Impact factor: 6.429

2.  Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors.

Authors:  Flavia Morales-Vásquez; Rocío Castillo-Sánchez; María J Gómora; Miguel Ángel Almaraz; Enrique Pedernera; Delia Pérez-Montiel; Elizabeth Rendón; Horacio Noé López-Basave; Edgar Román-Basaure; Sergio Cuevas-Covarrubias; Juan Maldonado-Cubas; Antonio Villa; Carmen Mendez
Journal:  J Ovarian Res       Date:  2020-07-28       Impact factor: 4.234

Review 3.  Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs).

Authors:  Loganathan Rangasamy; Bruno Di Geronimo; Irene Ortín; Claire Coderch; José María Zapico; Ana Ramos; Beatriz de Pascual-Teresa
Journal:  Molecules       Date:  2019-08-16       Impact factor: 4.411

4.  The prognostic values of matrix metalloproteinases in ovarian cancer.

Authors:  Linchai Zeng; Jie Qian; Fangfang Zhu; Fang Wu; Hongqin Zhao; Haiyan Zhu
Journal:  J Int Med Res       Date:  2019-05-17       Impact factor: 1.671

5.  Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.

Authors:  Hanfang Jiang; Huiping Li
Journal:  BMC Cancer       Date:  2021-02-10       Impact factor: 4.430

6.  Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.

Authors:  Qingyi Wang; Xiaoling Feng; Xiaofang Liu; Siyu Zhu
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

7.  Examining SNP-SNP interactions and risk of clinical outcomes in colorectal cancer using multifactor dimensionality reduction based methods.

Authors:  Aaron Curtis; Yajun Yu; Megan Carey; Patrick Parfrey; Yildiz E Yilmaz; Sevtap Savas
Journal:  Front Genet       Date:  2022-08-03       Impact factor: 4.772

Review 8.  An emerging role for BAG3 in gynaecological malignancies.

Authors:  Margot De Marco; Antonia Falco; Roberta Iaccarino; Antonio Raffone; Antonio Mollo; Maurizio Guida; Alessandra Rosati; Massimiliano Chetta; Giovanni Genovese; Francesco De Caro; Mario Capunzo; Maria Caterina Turco; Vladimir N Uversky; Liberato Marzullo
Journal:  Br J Cancer       Date:  2021-06-07       Impact factor: 9.075

9.  Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.

Authors:  Verena Hugenberg; Malte Behrends; Stefan Wagner; Sven Hermann; Michael Schäfers; Hartmuth C Kolb; Katrin Szardenings; Joseph C Walsh; Luis F Gomez; Klaus Kopka; Günter Haufe
Journal:  EJNMMI Radiopharm Chem       Date:  2018-07-27

10.  Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells.

Authors:  Alisha T Poole; Christopher A Sitko; Caitlin Le; Christian C Naus; Bryan M Hill; Eric A C Bushnell; Vincent C Chen
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.